Additionally, a total of 13 key inflammatory-immune related molecules, including chemokine-related molecules, interleukins, and CD4 T cell markers such as nuclear factor kappa B subunit 1 (NFKB1), were differentially expressed between MPS-I and MPS-II NB (Figure 7 D), strongly indicating that these specific genetic targets may have a high potential for future clinical treatments (Result S3). The gene discussed is CD4; the disease is mucopolysaccharidosis type 1.